Deals channel feed

No­vo Nordisk sees more to GLP-1's fu­ture in $600M pact with Flag­ship's Metaphore

Last year
Startups

Law­mak­ers con­sid­er lim­it­ing how long ex­ist­ing WuXi con­tracts can con­tin­ue

Last year
China
Discovery

Ex­clu­sive: Feng Zhang CRISPR start­up gath­ers patents, lock­ing up rights to fam­i­ly of edit­ing tech

Last year
R&D
Law

Il­lu­mi­na takes a step to­ward spin­ning off Grail, though keeps op­tion open for sale

Last year
Diagnostics

Chiesi bets $160M on Gos­samer Bio’s make-or-break late-stage PAH drug

Last year

FTC wants more in­for­ma­tion on No­vo-Catal­ent deal in an­titrust re­view

Last year
Manufacturing

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

Last year
Startups
Pharma

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Last year
Financing
Startups

Astel­las taps Po­sei­da for sec­ond CAR-T deal fo­cused on sol­id tu­mors

Last year
Cell/Gene Tx

Har­mo­ny Bio­sciences buys small epilep­sy biotech for $35M, plus mile­stones

Last year

No­var­tis hands Pep­tiDream $180M up­front to ex­tend ra­dio­phar­ma dis­cov­ery pact

Last year
R&D

Ono Phar­ma­ceu­ti­cal ac­quires De­ci­phera for $2.4B af­ter biotech's Phase 3 win

Last year

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

Last year
Startups
Pharma

Es­teve to ac­quire Per­rigo's rare dis­ease phar­ma busi­ness for up to $295M

Last year
Pharma

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

Last year

Cidara buys back flu rights, sells an­ti­fun­gal and inks $240M PIPE

Last year
Financing
Pharma

To bring bold promis­es to fruition, Mod­er­na col­lab­o­rates with Ope­nAI on Chat­G­PT tech

Last year
R&D

Ver­tex li­cens­es TreeFrog’s tech to up­scale cell ther­a­py man­u­fac­tur­ing for di­a­betes can­di­dates

Last year
Pharma
Manufacturing

One bid­der and a $5 hike: How Ver­tex inked $4.9B Alpine deal

Last year
Pharma

In­cyte inks $750M deal for im­mune and neu­ro biotech Escient

Last year
Startups

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Last year
Startups
R&D

Bris­tol My­ers, Cel­lares sign glob­al CAR-T deal as bio­phar­ma com­pa­nies look to di­ver­si­fy man­u­fac­tur­ing part­ners 

Last year
Cell/Gene Tx
Manufacturing

Ei­sai, BioArc­tic to de­vel­op new drug for Alzheimer’s that can cross blood-brain bar­ri­er

Last year
R&D

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Last year
R&D
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times